Nanjing Pharmaceutical Company Limited’s Net Profit Dropped 3.7% in First Half of 2023

Nanjing Pharmaceutical Company Limited (南京医药股份有限公司) (600713.SH) reported a net profit of 375.8 million yuan in the first half of 2023, down 3.7% year-on-year.

Meanwhile, the company posted 27.3 billion yuan in revenue, up 14.2% year-on-year.

At the end of the reporting period, it had 33.4 billion yuan in total assets and 26.4 billion yuan in total liabilities, with a liability-to-asset ratio of 79.2%.